By Professor Jason Grebely

Journal articles

Larney S; Leung J; Grebely J; Hickman M; Vickerman P; Peacock A; Stone J; Trickey A; Dumchev KV; Colledge S; Cunningham EB; Lynskey M; Mattick RP; Degenhardt L, 2020, 'Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence', International Journal of Drug Policy, 77, http://dx.doi.org/10.1016/j.drugpo.2019.102656

Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ; Peolim L; How-Chow D; Telenta J; Harvey P; Jones S; Dunlop A; Treloar C; Samuel Y; Poeder F; Crawford S; Baxter A; Keats J; Mowat Y; Silk D; Micallef M; Tamaddoni M; Marks P; Lamoury F; Jayasinghe I; Reid H; Cunningham EB; Bartlett S; Jacka B; Erratt A; Jauncey M; Collie P; Lam T; Gilliver R; Hazelwood S; Houlihan N; Burns C; Lewis R; Morris D; Donohue K; Carthew A; Horasak N; Cherry R; Shin S; Peterson D; Sellwood T; McKeown W; Pritchard-Jones J; Smyth F; Adey S; Clark K; Grebely J; Hajarizadeh B; Edwards M, 2020, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study', Journal of Viral Hepatitis, 27, pp. 281 - 293, http://dx.doi.org/10.1111/jvh.13233

Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C, 2020, 'Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting', International Journal of Drug Policy, 77, http://dx.doi.org/10.1016/j.drugpo.2020.102693

Colledge S; Larney S; Peacock A; Leung J; Hickman M; Grebely J; Farrell M; Degenhardt L, 2020, 'Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis', Drug and Alcohol Dependence, 207, http://dx.doi.org/10.1016/j.drugalcdep.2019.107793

Colledge S; Leung J; Larney S; Peacock A; Grebely J; Hickman M; Cunningham E; Trickey A; Stone J; Vickerman P; Degenhardt L, 2020, 'Frequency of injecting among people who inject drugs: A systematic review and meta-analysis', International Journal of Drug Policy, 76, http://dx.doi.org/10.1016/j.drugpo.2019.102619

Dore GJ; Martinello M; Alavi M; Grebely J, 2020, 'Global elimination of hepatitis C virus by 2030: why not?', Nature Medicine, 26, pp. 157 - 160, http://dx.doi.org/10.1038/s41591-019-0706-x

Fortier E; Sylvestre MP; Artenie AA; Minoyan N; Jutras-Aswad D; Roy É; Grebely J; Bruneau J, 2020, 'Associations between housing stability and injecting frequency fluctuations: findings from a cohort of people who inject drugs in Montréal, Canada', Drug and Alcohol Dependence, 206, http://dx.doi.org/10.1016/j.drugalcdep.2019.107744

Hines LA; Trickey A; Leung J; Larney S; Peacock A; Degenhardt L; Colledge S; Hickman M; Grebely J; Cunningham EB; Stone J; Dumchev K; Griffiths P; Vickerman P; Mattick RP; Lynskey M, 2020, 'Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis', Lancet Global Health, 8, pp. e76 - e91, http://dx.doi.org/10.1016/S2214-109X(19)30462-0

Marshall AD; Grebely J; Dore GJ; Treloar C, 2020, 'Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—The practitioner experience', Drug and Alcohol Dependence, 206, http://dx.doi.org/10.1016/j.drugalcdep.2019.107705

Jacka B; Larney S; Degenhardt L; Janjua N; Høj S; Krajden M; Grebely J; Bruneau J, 2020, 'Prevalence of injecting drug use and coverage of interventions to prevent HIV and hepatitis C virus infection among people who inject drugs in Canada', American Journal of Public Health, 110, pp. 45 - 50, http://dx.doi.org/10.2105/AJPH.2019.305379

Geddes L; Iversen J; Wand H; Esmaeili A; Tsui J; Hellard M; Dore G; Grebely J; Dietze P; Bruneau J; Prins M; Morris MD; Shoukry NH; Lloyd AR; Kim AY; Lauer G; Cox AL; Page K; Maher L; Lloyd A; Dore G; Dietze P, 2020, 'Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection', Clinical Infectious Diseases, 70, pp. 123 - 131, http://dx.doi.org/10.1093/cid/ciz162

Colledge S; Leung J; Larney S; Peacock A; Grebely J; Hickman M; Cunningham E; Trickey A; Stone J; Vickerman P; Degenhardt L, 2020, 'Frequency of injecting among people who inject drugs: A systematic review and meta-analysis.', Int J Drug Policy, 76, pp. 102619, http://dx.doi.org/10.1016/j.drugpo.2019.102619

Sharkawy RE; Bayoumi A; Metwally M; Mangia A; Berg T; Romero-Gomez M; Abate ML; Irving WL; Sheridan D; Dore GJ; Spengler U; Lampertico P; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Santoro R; Gallego-Durán R; Fischer J; Nattermann J; D’Ambrosio R; McLeod D; Powell E; latchoumanin O; Thabet K; Najim MAM; Douglas MW; Liddle C; Qiao L; George J; Eslam M; White R; Rojas A; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR, 2019, 'A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms', Scientific Reports, 9, http://dx.doi.org/10.1038/s41598-018-35736-2

Catlett B; Lamoury FMJ; Bajis S; Hajarizadeh B; Martinez D; Mowat Y; Cunningham PH; Jacka BP; Cloherty GA; Marks P; Dore GJ; Grebely J; Applegate TL, 2019, 'Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study', Journal of Viral Hepatitis, 26, pp. 1423 - 1430, http://dx.doi.org/10.1111/jvh.13196

Trickey A; Fraser H; Lim AG; Walker JG; Peacock A; Colledge S; Leung J; Grebely J; Larney S; Martin NK; Degenhardt L; Hickman M; May MT; Vickerman P, 2019, 'Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study', Journal of Viral Hepatitis, 26, pp. 1388 - 1403, http://dx.doi.org/10.1111/jvh.13187

Safreed-Harmon K; Blach S; Aleman S; Bollerup S; Cooke G; Dalgard O; Dillon JF; Dore GJ; Duberg AS; Grebely J; Boe Kielland K; Midgard H; Porter K; Razavi H; Tyndall M; Weis N; Lazarus JV, 2019, 'The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination', Clinical Infectious Diseases, 69, pp. 2218 - 2227, http://dx.doi.org/10.1093/cid/ciz714

Lafferty L; Rance J; Treloar C, 2019, '‘Fighting a losing battle’: prisoners’ perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures', Drugs Education Prevention and Policy, 26, pp. 502 - 507, http://dx.doi.org/10.1080/09687637.2018.1494135

Colledge S; Peacock A; Leung J; Larney S; Grebely J; Hickman M; Cunningham E; Trickey A; Stone J; Vickerman P; Degenhardt L; Peacock A, 2019, 'The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis', International Journal of Drug Policy, 73, pp. 172 - 184, http://dx.doi.org/10.1016/j.drugpo.2019.07.030

Degenhardt L; Grebely J; Stone J; Hickman M; Vickerman P; Marshall BDL; Bruneau J; Altice FL; Henderson G; Rahimi-Movaghar A; Larney S, 2019, 'Global patterns of opioid use and dependence: harms to populations, interventions, and future action', Lancet, 394, pp. 1560 - 1579, http://dx.doi.org/10.1016/S0140-6736(19)32229-9

Alavi M; Poustchi H; Merat S; Kaveh-ei S; Rahimi-Movaghar A; Shadloo B; Hajarizadeh B; Grebely J; Dore GJ; Malekzadeh R, 2019, 'An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study', International Journal of Drug Policy, 72, pp. 99 - 105, http://dx.doi.org/10.1016/j.drugpo.2019.07.002

Selfridge M; Cunningham EB; Milne R; Drost A; Barnett T; Lundgren K; Guarasci K; Grebely J; Fraser C, 2019, 'Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada', International Journal of Drug Policy, 72, pp. 106 - 113, http://dx.doi.org/10.1016/j.drugpo.2019.03.001

Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C, 2019, 'Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all', International Journal of Drug Policy, 72, pp. 1 - 10, http://dx.doi.org/10.1016/j.drugpo.2019.07.016

Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ, 2019, 'Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia', Journal of Hepatology, 71, pp. 281 - 288, http://dx.doi.org/10.1016/j.jhep.2019.04.014

Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ, 2019, 'Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study', Journal of Viral Hepatitis, 26, pp. 969 - 979, http://dx.doi.org/10.1111/jvh.13112

Bao Y; Larney S; Peacock A; Colledge S; Grebely J; Hickman M; Degenhardt L; Leung J, 2019, 'Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis', International Journal of Drug Policy, 70, pp. 87 - 93, http://dx.doi.org/10.1016/j.drugpo.2019.05.005

Fortier E; Artenie AA; Zang G; Jutras-Aswad D; Roy É; Grebely J; Bruneau J, 2019, 'Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada', Addiction, 114, pp. 1495 - 1503, http://dx.doi.org/10.1111/add.14632

Abayasingam A; Leung P; Eltahla A; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Cox AL; Kim AY; Schinkel J; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd A; Rodrigo C, 2019, 'Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing', Infection Genetics and Evolution, 71, pp. 36 - 41, http://dx.doi.org/10.1016/j.meegid.2019.02.032

Leung J; Peacock A; Colledge S; Grebely J; Cunningham EB; Hickman M; Vickerman P; Stone J; Trickey A; Dumchev K; Lynskey M; Hines L; Griffiths P; Mattick RP; Degenhardt L; Larney S, 2019, 'A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus among People Who Inject Drugs - Do Gender-Based Differences Vary by Country-Level Indicators?', Journal of Infectious Diseases, 220, pp. 78 - 90, http://dx.doi.org/10.1093/infdis/jiz058

Trickey A; Fraser H; Lim AG; Peacock A; Colledge S; Walker JG; Leung J; Grebely J; Larney S; Martin NK; Hickman M; Degenhardt L; May MT; Vickerman P, 2019, 'The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study', Lancet Gastroenterology and Hepatology, 4, pp. 435 - 444, http://dx.doi.org/10.1016/S2468-1253(19)30085-8

Olmstead AD; Montoya V; Chui CK; Dong W; Joy JB; Tai V; Poon AFY; Nguyen T; Brumme CJ; Martinello M; Matthews GV; Richard Harrigan P; Dore GJ; Applegate TL; Grebely J; Howe AYM, 2019, 'A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections', Infection Genetics and Evolution, 69, pp. 76 - 84, http://dx.doi.org/10.1016/j.meegid.2019.01.016

Rodrigo C; Leung P; Lloyd AR; Bull RA; Luciani F; Grebely J; Dore GJ; Applegate T; Page K; Bruneau J; Cox AL; Osburn W; Kim AY; Shoukry NH; Lauer GM; Maher L; Schinkel J; Prins M; Hellard M; Eltahla AA, 2019, 'Genomic variability of within-host hepatitis C variants in acute infection', Journal of Viral Hepatitis, 26, pp. 476 - 484, http://dx.doi.org/10.1111/jvh.13051

Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J, 2019, 'Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs', International Journal of Drug Policy, 66, pp. 87 - 93, http://dx.doi.org/10.1016/j.drugpo.2019.01.012

Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ, 2019, 'Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy', International Journal of Drug Policy, 66, pp. 73 - 79, http://dx.doi.org/10.1016/j.drugpo.2019.01.011

Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Filep E; Petoumenos K; Marks P; Applegate T; Grebely J; Dore G; Nelson M; Matthews G, 2019, 'Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection', JOURNAL OF HEPATOLOGY, 70, pp. E231 - E231, http://dx.doi.org/10.1016/S0618-8278(19)30432-3

Safreed-Harmon K; Blach S; Aleman S; Kielland KB; Bollerup S; Cooke G; Dalgard O; Dillon J; Dore G; Du Berg A-S; Grebely J; Midgard H; Porter K; Razavi H; Tyndall M; Weis N; Lazarus J, 2019, 'The consensus hepatitis C cascade of care: Methodology and initial findings from three countries', JOURNAL OF HEPATOLOGY, 70, pp. E333 - E334, http://dx.doi.org/10.1016/S0618-8278(19)30651-6

Catlett B; Carrera A; Starr M; Applegate TL; Lowe P; Philip Cunningham H; Grebely J, 2019, 'Performance evaluation of the Hologic Aptima HCV Quant Dx assay for detection of HCV RNA from dried blood spots', Journal of Clinical Virology, 112, pp. 40 - 44, http://dx.doi.org/10.1016/j.jcv.2019.01.010

Bartlett SR; Applegate TL; Jacka BP; Martinello M; Lamoury FMJ; Danta M; Bradshaw D; Shaw D; Lloyd AR; Hellard M; Dore GJ; Matthews GV; Grebely J, 2019, 'A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015', Journal of the International AIDS Society, 22, pp. e25222, http://dx.doi.org/10.1002/jia2.25222

Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L, 2019, 'Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia', Journal of Hepatology, 70, pp. 33 - 39, http://dx.doi.org/10.1016/j.jhep.2018.09.030

Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT; Dunlop A; Zekry A; Lloyd A; Duvnjak A; Treloar C; Tyrrell H; George J; Iversen J; Marriott K; Crooks L; Maher L; Douglas M, 2019, 'Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study', Journal of Viral Hepatitis, 26, pp. 83 - 92, http://dx.doi.org/10.1111/jvh.13013

Foster GR; Dore GJ; Wang S; Grebely J; Sherman KE; Baumgarten A; Conway B; Jackson D; Asselah T; Gschwantler M; Tomasiewicz K; Aguilar H; Asatryan A; Hu Y; Mensa FJ, 2019, 'Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies', Drug and Alcohol Dependence, 194, pp. 487 - 494, http://dx.doi.org/10.1016/j.drugalcdep.2018.11.007

Grebely J; Larney S; Peacock A; Colledge S; Leung J; Hickman M; Vickerman P; Blach S; Cunningham EB; Dumchev K; Lynskey M; Stone J; Trickey A; Razavi H; Mattick RP; Farrell M; Dore GJ; Degenhardt L, 2019, 'Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs', Addiction, 114, pp. 150 - 166, http://dx.doi.org/10.1111/add.14393

Day E; Hellard M; Treloar C; Bruneau J; Martin NK; Øvrehus A; Dalgard O; Lloyd A; Dillon J; Hickman M; Byrne J; Litwin A; Maticic M; Bruggmann P; Midgard H; Norton B; Trooskin S; Lazarus JV; Grebely J, 2019, 'Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework', Liver International, 39, pp. 20 - 30, http://dx.doi.org/10.1111/liv.13949

Grebely J; Drolet M; Nwankwo C; Torrens M; Kastelic A; Walcher S; Somaini L; Mulvihill E; Ertl J; Liebert R; Litwin AH, 2019, 'Perceptions and self-reported competency related to testing, management and treatment of hepatitis C virus infection among physicians prescribing opioid agonist treatment: The C-SCOPE study', International Journal of Drug Policy, 63, pp. 29 - 38, http://dx.doi.org/10.1016/j.drugpo.2018.10.012

Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C; Amin J; Bruggmann P; Lacombe K; Stedman C; Hellard M; Marks P; Dunlop A; Moriggia A; Applegate T; Litwin A; Matthews G; Dore G, 2019, 'SAT-232-Reinfection following successful HCV DAA therapy among people with recent injecting drug use', Journal of Hepatology, 70, pp. e732 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31465-3

Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore G; Grebely J, 2019, 'SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', Journal of Hepatology, 70, pp. e733 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31466-5

Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B; Dunlop AJ; Norton B; Litwin AH; Hajarizadeh B; Thurnheer MC; Dillon JF; Weltman M; Shaw D; Bruggmann P; Gane E; Fraser C; Marks P; Applegate TL; Quiene S; Siriragavan S; Matthews GV; Dore GJ; Grebely J, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013

Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004

Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C, 2018, 'Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison', Journal of Viral Hepatitis, 25, pp. 1526 - 1532, http://dx.doi.org/10.1111/jvh.12987

Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J, 2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, 61, pp. 23 - 30, http://dx.doi.org/10.1016/j.drugpo.2018.08.011

Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J, 2018, 'Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis', Lancet Gastroenterology and Hepatology, 3, pp. 754 - 767, http://dx.doi.org/10.1016/S2468-1253(18)30304-2

Back to profile page